ClinicalTrials.gg
Not yet recruitingNCT07721922Updated Oct 19, 2026

Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD)

A Phase 4 interventional study of Revefenacin and formoterol fumarate in COPD Exacerbation, sponsored by University of Tennessee Graduate School of Medicine. Not yet recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Tennessee Graduate School of Medicine · Phase 4, Interventional, and Treatment

How we know

Updated Oct 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. revefenacin · Pulmonary Disease, Chronic Obstructive.

Planned enrollment
6th of 17
280 · median 122
Started
2026
the only one that year
Phase 4
4 of 17
2 open now
Registered
17th of 17
by date
Lead sponsor
3 of 17
University of Tennessee Graduate School of Medicine

Among the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 4, and was the 17th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About revefenacin

revefenacin: first FDA approval 2018 (YUPELRI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing revefenacin in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The primary aim is to determine whether nebulized Formoterol twice daily plus Revefenacin once daily is non-inferior to standard-of-care nebulized Albuterol and Ipratropium therapy four times daily in relieving dyspnea among patients with ECOPD presenting to the ED and requiring hospitalization, as measured by the Modified Borg Dyspnea Scale.

The hypothesize is that patients in the ED for ECOPD, improvement in symptoms, safety, and length of ED or hospital stay after treatment with nebulized Revefenacin and Formoterol will be non-inferior to the Albuterol and Ipratropium combination. The long-acting bronchodilator regimen will provide comparable symptom control with fewer total drug doses compared with standard treatment with short-acting bronchodilators, namely, nebulized Albuterol and Ipratropium. To the best of our knowledge, this will be the first prospective, randomized, double-blind investigation to compare a combination of long-acting nebulized LAMA/LABA bronchodilators with a standard-of-care combination of short-acting nebulized SAMA/SABA bronchodilators in patients with an ECOPD in the ED/hospital setting.

03

Conditions studied

  • COPD Exacerbation

Keywords

  • ECOPD
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or Female
  2. Any Race
  3. ≥ 40 years of age
  4. History of based on EMR or confirmed verbally by the patient
  5. Presenting to the ED with a primary diagnosis of ECOPD or acute respiratory failure with a secondary diagnosis of COPD
  6. Able to understand and comply with study procedures
  7. Willingness to sign and date an Form

Exclusion criteria

Exclusion Criteria:

  1. Patients unable or unwilling to sign an or cooperate with study procedures
  2. Patients who are hypersensitive to Formoterol or Revefenacin
  3. Patients who are intubated, have tracheotomy, are receiving mechanical ventilation by mask or artificial airway
  4. Patients who have previously participated in the study
  5. Patients, in the opinion of the investigators, who are rapidly decompensating and are immediately in need, or will soon need, ventilator support based on:

    i. Inability to maintain respiratory effort ii. Cyanosis iii. Hemodynamic instability iv. Deterioration in mental status

  6. Patients who, per the investigator, have unstable cardiovascular disease (e.g., uncontrolled hypertension, unstable angina, recent MI (within 12 weeks), ventricular arrhythmia, or decompensated heart failure)
  7. Patients with a current diagnosis of lung cancer requiring treatment
  8. Pulmonary diseases other than , or lobar pneumonia
  9. Patients with acute psychiatric illness deemed significant by the investigator
  10. Patients with a history of glaucoma deemed significant by the investigator
  11. History of urinary retention deemed significant by the investigator
  12. Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Group 1: Revefenacin (YUPELRI) & Formoterol (Perforomist)

    Participants will receive Revefenacin 175 µg once daily and Formoterol 20 µg twice daily via a jet nebulizer for up to 7 days or until hospital discharge (if discharge occurs before Day 7). Participants will also receive placebo (sterile normal saline) to maintain blinding and mask the difference in dosing frequency compared with the comparator arm.

    Drug: Revefenacin · Drug: formoterol fumarate · Other: Placebo (Sterile Normal Saline)

  • Active comparator
    Group2: Ipratropium Bromide (Atrovent) & Albuterol (Ventolin)

    Albuterol and Ipratropium every 6 hours nebulized over the 7-day treatment period or until discharge if prior to day 7.

    Drug: Albuterol sulfate · Drug: Ipratropium Bromide

Interventions

  • Revefenacin 175 µg in 3 mL inhalation solution administered once daily in the morning via oral inhalation using a jet nebulizer.

    Also known as: YUPELRI

  • DrugFormoterolStudies of FormoterolFormoterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Formoterol fumarate 20 μg in 2 mL inhalation solution administered twice daily in the morning and evening via oral inhalation using a jet nebulizer.

    Also known as: Perforomist

  • OtherPlacebo (Sterile Normal Saline)

    Twice daily (sterile normal saline 3 ml) to maintain blinding and mask the difference in dosing frequency compared with the comparator arm.

  • DrugAlbuterolStudies of AlbuterolAlbuterol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Albuterol sulfate 2.5 mg in 3 mL inhalation solution administered 4 times daily via oral inhalation using a jet nebulizer.

    Also known as: Ventolin

  • DrugIpratropiumStudies of IpratropiumIpratropium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ipratropium Bromide 500 μg in 2.5 mL inhalation solution administered 4 times daily via oral inhalation using a jet nebulizer.

    Also known as: Atrovent

06

What researchers measure

Primary outcomes

  1. Difference in Modified Borg Dyspnea Scale scores between groups

    This is a scale asks the subject to rate the difficulty of their breathing. It starts at number 0 where breathing is causing no difficulty at all and progresses through to number 10 where breathing difficulty is maximal. This will be recorded prior to dosing twice a day between 7 and 9 am \& pm. Scores from Group 1 and Group 2 will be averaged and compared.

    Time frame: From enrollment through Day 7 (end of treatment)

Secondary outcomes

  1. Number of patients discharged home from the ED

    Time frame: From enrollment through Day 7 (end of treatment)

  2. Number of patients admitted to a hospital floor or require ED observation for >24 hours (in-hospital patients)

    Time frame: From enrollment through Day 7 (end of treatment)

  3. Length of hospital or ED stay

    Time frame: From enrollment through Day 7 (end of treatment)

  4. Number of Participants with the Need to Switch Therapy

    Time frame: From enrollment through Day 7 (end of treatment)

  5. Total number of bronchodilator doses per hospital or ED stay

    Time frame: From enrollment through Day 7 (end of treatment)

  6. Total number of rescue doses used

    Time frame: From enrollment through Day 7 (end of treatment)

  7. Number of Participants with Failure of Treatment (Need for Mechanical Ventilation or Death

    Failure of treatment will be defined as any of the following: death, the need for a patient to receive mechanical ventilation, or the need for a patient to discontinue long-acting bronchodilators during the trial. The need for rescue medications while maintaining the assigned treatment will not be considered a failure of treatment.

    Time frame: From enrollment through Day 7 (end of treatment)

  8. Number of Participants Requiring Supplemental Oxygen

    Time frame: From enrollment through Day 7 (end of treatment)

  9. Differences in FEV1/FVC values between enrollment and discharge/end of study.

    Bedside spirometry will be performed by respiratory therapists with the patient in a sitting position using a handheld portable spirometer. The patient will be asked to make a tight seal around the mouthpiece with their lips and forcefully exhale after a deep inhalation. The patient will be instructed to continue forceful and rapid exhalation until no more air is expelled from their lungs. The best of 3 efforts will be used for analysis. FEV1/FVC\<0.7 will be used to diagnose airflow obstruction.

    Time frame: From enrollment through Day 7 (end of treatment)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 21 months later.

Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 21 months is below that.

Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jul 23, 2026
StartEst.
Nov 12, 2026was Sep 2026
Primary completionEst.
Sep 1, 2028
CompletionEst.
Sep 1, 2028
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 1, 2026→Nov 12, 2026
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Start date Sep 1, 2026→Nov 12, 2026
    + 1 other change: documents

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07721922
Lead sponsor
University of Tennessee Graduate School of Medicine
Collaborators
Viatris Inc.
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
Nov 12, 2026 (estimated)
Primary completion
Sep 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Oct 19, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Revefenacin · Formoterol

Start the discussion